Overview

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Status:
Completed
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Collaborator:
Sanofi